From detecting early disease to guiding treatment plans, clinicians are finding ctDNA testing increasingly important.

Nurses play an important role in the administration of biosimilars and the education of patients receiving them.

This past year, the role of ctDNA testing has expanded to guide treatment decisions for providers and patients with cancer.

According to real-world data, no survival advantage was seen when comparing 3 frontline CDK4/6 inhibitor combinations in ...

Adjuvant olaparib continued to show a strong efficacy benefit in patients with BRCA1/2 mutation–positive, HER2-negative high-risk breast, according to 6-year data from the OlympiA trial.

Patients administered lymphodepletion prior to brexu-cel in the outpatient setting experienced a 60-day non-relapse mortality rate of 3.6% in B-ALL and MCL. Lymphodepletion in the outpatient setting, ...

The combination of selinexor with ruxolitinib, in both 40mg and 60mg doses, demonstrated encouraging efficacy with a manageable safety profile in patients with myelofibrosis. Treatment with selinexor ...

An FDA approval was granted for cosibelimab-ipdl for the treatment of patients with locally advanced or metastatic cutaneous squamous cell carcinoma. Cosibelimab-ipdl (Unloxcyt) has been granted FDA ...

Novel Drug Combo Is Promising for PD-L1-Resistant Solid Cancers ...